Melanoma biology and new targeted therapy

被引：1078

作者：

Gray-Schopfer, Vanessa ^{[1
]}

Wellbrock, Claudia ^{[1
]}

Marais, Richard ^{[1
]}

机构：

[1] Canc Res UK, Inst Canc Res, Signal Transduct Team, Ctr Cell & Mol Biol, London SW3 6JB, England

来源：

NATURE | 2007年 / 445卷 / 7130期

关键词：

D O I：

10.1038/nature05661

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Melanoma is a cancer that arises from melanocytes, specialized pigmented cells that are found predominantly in the skin. The incidence of melanoma is rising steadily in western populations - the number of cases worldwide has doubled in the past 20 years. In its early stages malignant melanoma can be cured by surgical resection, but once it has progressed to the metastatic stage it is extremely difficult to treat and does not respond to current therapies. Recent discoveries in cell signalling have provided greater understanding of the biology that underlies melanoma, and these advances are being exploited to provide targeted drugs and new therapeutic approaches.

引用

收藏

页码：851 / 857

页数：7

相关论文

共 101 条

[1] Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background [J].

Ackermann, J ;

Frutschi, M ;

Kaloulis, K ;

McKee, T ;

Trumpp, A ;

Beermann, F .

CANCER RESEARCH, 2005, 65 (10) :4005-4011

[2] Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature [J].

Adnane, Lila ;

Trail, Pamela A. ;

Taylor, Ian ;

Wilhelm, Scott M. .

REGULATORS AND EFFECTORS OF SMALL GTPASES: RAS FAMILY, 2006, 407 :597-+

[3] Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: Implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma [J].

Amiri, KI ;

Horton, LW ;

LaFleur, BJ ;

Sosman, JA ;

Richmond, A .

CANCER RESEARCH, 2004, 64 (14) :4912-4918

[4] Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group [J].

Bedikian, Agop Y. ;

Millward, Michael ;

Pehamberger, Hubert ;

Conry, Robert ;

Gore, Martin ;

Trefzer, Uwe ;

Pavlick, Anna C. ;

DeConti, Ronald ;

Hersh, Evan M. ;

Hersey, Peter ;

Kirkwood, John M. ;

Haluska, Frank G. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4738-4745

[5] Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase cascade is regulated by IκB kinase-induced proteolysis of NF-κB1 p105 [J].

Beinke, S ;

Robinson, MJ ;

Hugunin, M ;

Ley, SC .

MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (21) :9658-9667

[6] Human melanocyte senescence and melanoma susceptibility genes [J].

Bennett, DC .

ONCOGENE, 2003, 22 (20) :3063-3069

[7] Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling [J].

Bhatt, KV ;

Spofford, LS ;

Aram, G ;

McMullen, M ;

Pumiglia, K ;

Aplin, AE .

ONCOGENE, 2005, 24 (21) :3459-3471

[8]

BOHM M, 1995, CELL GROWTH DIFFER, V6, P291

[9] Molecular basis of congenital hypopigmentary disorders in humans: A review [J].

Boissy, RE ;

Nordlund, JJ .

PIGMENT CELL RESEARCH, 1997, 10 (1-2) :12-24

[10] BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice [J].

Burke, JR ;

Pattoli, MA ;

Gregor, KR ;

Brassil, PJ ;

MacMaster, JF ;

McIntyre, KW ;

Yang, XX ;

Iotzova, VS ;

Clarke, W ;

Strnad, J ;

Qiu, YP ;

Zusi, FC .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (03) :1450-1456

← 1 2 3 4 5 6 7 8 9 10 →